Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica Gluck"'
Publikováno v:
Circulation Research. 131
Heart disease is the leading cause of death in the U.S. and worldwide. Cardiac tissue engineering offers promising diagnostic tools and treatments. Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are an attractive cell source f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::471623010e1bbad3233b54abb7e293b8
https://doi.org/10.1161/res.131.suppl_1.p1127
https://doi.org/10.1161/res.131.suppl_1.p1127
Autor:
David Digomann, Max Heiduk, Charlotte Reiche, Jessica Glück, Christoph Kahlert, Peter Mirtschink, Anna Klimova, Florian Bösch, Torsten Tonn, Jochen Gaedcke, Michael Ghadimi, Jürgen Weitz, Lena Seifert, Adrian M. Seifert
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-9 (2023)
Abstract Pancreatic ductal adenocarcinoma (PDAC) responds poorly to systemic treatment, including new immunotherapeutic approaches. Biomarkers are urgently needed for early disease detection, patient stratification for treatment, and response predict
Externí odkaz:
https://doaj.org/article/c19f5bd9248f4e8393bbb8bdfd097f13
Publikováno v:
Circulation. 132
Human induced pluripotent stem cells (hiPSCs) with the ability to form all somatic cells can generate pacemaking cardiomyocytes (CMs) for engineering of biological pacemakers. However, differentiation efficiency of hiPSCs into pacemaking cardiomyocyt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f38c8a5c24e56cb55eb4cccf201a1ebc
https://doi.org/10.1161/circ.132.suppl_3.17442
https://doi.org/10.1161/circ.132.suppl_3.17442
Autor:
Max Heiduk, Ioana Plesca, Jessica Glück, Luise Müller, David Digomann, Charlotte Reiche, Janusz von Renesse, Rahel Decker, Christoph Kahlert, Ulrich Sommer, Daniela E. Aust, Marc Schmitz, Jürgen Weitz, Lena Seifert, Adrian M. Seifert
Publikováno v:
JCI Insight, Vol 7, Iss 22 (2022)
BACKGROUND Pancreatic ductal adenocarcinoma (PDAC) has a dismal prognosis. At diagnosis, only 20% of patients with PDAC are eligible for primary resection. Neoadjuvant chemotherapy can enable surgical resection in 30%–40% of patients with locally a
Externí odkaz:
https://doaj.org/article/9a5a29027fcc4aadb45aea3cef95ab9a